MCID: MNT002
MIFTS: 62

Mental Depression

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 15 73
Depressive Disorder 73
Depression 44

Classifications:



External Ids:

Disease Ontology 12 DOID:1596
ICD10 33 F32.9 F33.9
MeSH 44 D003863
NCIt 50 C2982
SNOMED-CT 68 41006004

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to atypical depressive disorder and postpartum depression, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is IER3IP1 (Immediate Early Response 3 Interacting Protein 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1336)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 33.8 CRH HTR2A HTR7 MAOA SLC6A4
2 postpartum depression 33.7 BDNF COMT CRH IER3IP1 MAOA OXT
3 major depressive disorder 33.0 TPH2 SLC6A4 SLC6A2 PSMD9 POMC OXT
4 bipolar disorder 32.9 BDNF COMT CRH HTR1A HTR2A HTR2C
5 dysthymic disorder 32.2 GATA3 HTR2A HTR7 MAOA SLC6A4
6 schizoaffective disorder 32.2 BDNF COMT HTR2A SLC6A4
7 depression 32.1 BDNF CRH HTR1A HTR2A HTR2C MAOA
8 irritable bowel syndrome 32.0 CRH HTR7 SLC6A4
9 fibromyalgia 31.9 COMT CRH HTR2A SLC6A4
10 bulimia nervosa 31.8 BDNF COMT HTR2A SLC6A4
11 asperger syndrome 31.8 BDNF OXT SLC6A4
12 anxiety 31.8 TPH2 SLC6A4 OXT MAOA HTR2C HTR2A
13 eating disorder 31.8 BDNF COMT CRH HTR2C POMC SLC6A4
14 parkinson disease, late-onset 31.7 BDNF COMT HTR1A HTR2A IER3IP1 MAOA
15 autism spectrum disorder 31.7 BDNF HTR2A OXT SLC6A4 TPH2
16 bipolar i disorder 31.7 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
17 kleine-levin hibernation syndrome 31.5 COMT CORT HTR7 POMC
18 schizophrenia 31.5 BDNF COMT HTR1A HTR2A HTR2C HTR7
19 borderline personality disorder 31.5 BDNF COMT HTR1A HTR2A HTR2C MAOA
20 migraine with or without aura 1 31.4 COMT HTR1A HTR2A HTR2C HTR7 IER3IP1
21 mood disorder 31.2 TPH2 SLC6A4 SLC6A2 POMC MAOA HTR2C
22 endogenous depression 31.2 BDNF CRH HTR1A HTR2A HTR7 IER3IP1
23 melancholia 30.9 CRH IER3IP1
24 alexithymia 30.9 COMT HTR1A SLC6A4
25 alcohol abuse 30.8 BDNF HTR2A SLC6A4
26 social phobia 30.7 HTR1A MAOA SLC6A4
27 personality disorder 30.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
28 conduct disorder 30.6 COMT MAOA SLC6A4
29 sexual disorder 30.6 HTR1A OXT SLC6A4
30 substance abuse 30.6 BDNF COMT MAOA SLC6A4
31 tobacco addiction 30.5 COMT HTR2A MAOA SLC6A4
32 generalized anxiety disorder 30.5 BDNF COMT HTR1A HTR2A MAOA PSMD9
33 agoraphobia 30.5 HTR1A MAOA SLC6A2 SLC6A4
34 post-traumatic stress disorder 30.4 BDNF COMT CRH FKBP5 HTR2A MAOA
35 substance dependence 30.3 BDNF MAOA POMC SLC6A4
36 premenstrual tension 30.3 CRH OXT POMC
37 tardive dyskinesia 30.1 COMT HTR2A
38 drug dependence 30.1 BDNF CRH POMC SLC6A4
39 psychotic disorder 30.1 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
40 antisocial personality disorder 30.1 COMT MAOA SLC6A4
41 pathological gambling 30.1 HTR2A MAOA SLC6A4
42 alcohol dependence 30.0 BDNF COMT HTR1A HTR2A HTR2C MAOA
43 chronic fatigue syndrome 30.0 COMT CRH HTR1A HTR2A MAOA POMC
44 withdrawal disorder 30.0 CRH HTR7 POMC
45 oppositional defiant disorder 30.0 COMT MAOA SLC6A2 SLC6A4 TPH2
46 anorexia nervosa 29.9 BDNF COMT CRH HTR2A OXT POMC
47 obsessive-compulsive disorder 29.9 TPH2 SLC6A4 OXT MAOA HTR2C HTR2A
48 panic disorder 29.9 TPH2 SLC6A4 SLC6A2 POMC MAOA HTR2C
49 premature ejaculation 29.9 COMT HTR1A HTR2C SLC6A4
50 paranoid schizophrenia 29.8 BDNF COMT HTR2A MAOA SLC6A4 TPH2

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

GenomeRNAi Phenotypes related to Mental Depression according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.28 DCTN1 MAOA
2 Decreased viability GR00240-S-1 10.28 COMT CORT
3 Decreased viability GR00381-A-1 10.28 CORT HTR1A SLC6A4
4 Decreased viability GR00381-A-2 10.28 CORT
5 Decreased viability GR00381-A-3 10.28 CORT HTR1A SLC6A4
6 Decreased viability GR00402-S-2 10.28 BDNF COMT CORT CRH DCTN1 DPP4
7 no effect GR00402-S-1 9.62 BDNF COMT CORT CRH DCTN1 DPP4

MGI Mouse Phenotypes related to Mental Depression:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 BDNF COMT CORT CRH DCTN1 FKBP5
2 homeostasis/metabolism MP:0005376 10.19 BDNF COMT CORT CRH DCTN1 DPP4
3 endocrine/exocrine gland MP:0005379 10.07 BDNF COMT CORT CRH DPP4 GATA3
4 cardiovascular system MP:0005385 10.06 COMT GATA3 HTR1A MAOA OXT POMC
5 growth/size/body region MP:0005378 10.06 BDNF CORT CRH DPP4 GATA3 HTR2C
6 adipose tissue MP:0005375 9.93 CRH GATA3 HTR2C OXT POMC TPH2
7 integument MP:0010771 9.85 BDNF CRH GATA3 HTR2C HTR7 OXT
8 mortality/aging MP:0010768 9.73 BDNF DCTN1 FKBP5 GATA3 HTR1A HTR2C
9 nervous system MP:0003631 9.47 BDNF COMT CRH DCTN1 GATA3 HTR1A

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
4
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
5
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68-41-7 6234 401
6
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
7
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 1622-61-3 2802
8
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
9
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
10
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
11
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 91374-21-9, 91374-20-8 497540 5095
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
13
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
14 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
15
Copper Approved, Investigational Phase 4,Phase 3 7440-50-8 27099
16
Norethindrone Approved Phase 4 68-22-4 6230
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
18
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
19
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
20
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
21
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24219-97-4 4184
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
23
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61337-67-5, 85650-52-8 4205
24
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
25
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
26
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
27
Nortriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72-69-5 4543
28
Trimipramine Approved Phase 4,Phase 3 739-71-9 5584 4055
29
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
30
Buspirone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 36505-84-7 2477
31
Reboxetine Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 98769-81-4, 71620-89-8 123628 65856
32
Eszopiclone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138729-47-2 969472
33
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
34
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
35
Lactulose Approved Phase 4 4618-18-2 11333
36
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
37
Promethazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-87-7 4927
38
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
39
Suvorexant Approved, Investigational Phase 4 1030377-33-3
40
Methimazole Approved Phase 4 60-56-0 1349907
41
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54739-18-3 3404 5324346
42
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-22-0 6013
43
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-18-4 6010
44
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Not Applicable 315-37-7 9416
45
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5949-44-0
46
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
47
Succinylcholine Approved Phase 4,Not Applicable 306-40-1 5314
48
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 616-91-1 12035
49
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
50
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 508233-74-7 9966051

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
2 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
3 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
4 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
5 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
6 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
7 Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine Unknown status NCT02989727 Phase 4 Lamotrigine;Placebos
8 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
9 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
10 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
11 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
12 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
13 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
14 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
15 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
16 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
17 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
18 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
19 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
20 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
21 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
22 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
23 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
24 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
25 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
26 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
27 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
28 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
29 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
30 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
31 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
32 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
33 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
34 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
35 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
36 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
37 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
38 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
39 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
40 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
41 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
42 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
43 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
44 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
45 Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study Unknown status NCT00785603 Phase 4 Paroxetine;Paroxetin placebo;Tramadol
46 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
47 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
48 Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone Unknown status NCT01849861 Phase 4 Methimazole
49 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
50 Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

41
Brain, Testes, Heart, Cortex, Prefrontal Cortex, Amygdala, Pituitary

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 958)
# Title Authors Year
1
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. ( 30292023 )
2019
2
Symptoms of social anxiety disorder and major depressive disorder: A network perspective. ( 30292147 )
2019
3
Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. ( 30248637 )
2019
4
Corrigendum to "Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: An admixture analysis and complex network analysis." [Journal of Affective Disorders, 199 (2016) 99-105]. ( 30189353 )
2019
5
Transcranial Magnetic Stimulation in Conditions Other than Major Depressive Disorder. ( 30389075 )
2019
6
Health, pre-disease and critical transition to disease in the psycho-immune-neuroendocrine network: Are there distinct states in the progression from health to major depressive disorder? ( 30393143 )
2019
7
Altered hippocampal function with preserved cognitive performance in treatment-naive major depressive disorder. ( 30422941 )
2019
8
Cortical thickness in major depressive disorder: A systematic review and meta-analysis. ( 30118825 )
2019
9
Similar profiles of cognitive domain deficits between medication-naïve patients with bipolar II depression and those with major depressive disorder. ( 30227315 )
2019
10
Severity-dependent and -independent brain regions of major depressive disorder: A long-term longitudinal near-infrared spectroscopy study. ( 30248636 )
2019
11
Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms. ( 30248638 )
2019
12
Aberrant cortical neurodevelopment in major depressive disorder. ( 30261449 )
2019
13
A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. ( 30286415 )
2019
14
Alterations in patients with major depressive disorder before and after electroconvulsive therapy measured by fractional amplitude of low-frequency fluctuations (fALFF). ( 30326347 )
2019
15
Assessment of the psychometric properties of the 17- and 6-item Hamilton Depression Rating Scales in major depressive disorder, bipolar depression and bipolar depression with mixed features. ( 30055852 )
2019
16
Association between baseline pro-inflammatory cytokines and brain activation during social exclusion in patients with vulnerability to suicide and depressive disorder. ( 30326381 )
2019
17
Corrigendum to 'Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis' [Journal of Psychiatric Research 104 (2018) 144-156]. ( 30408654 )
2019
18
The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence. ( 30006604 )
2018
19
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2018
20
Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy. ( 29927088 )
2018
21
Emotional Roles of Mono-Aminergic Neurotransmitters in Major Depressive Disorder and Anxiety Disorders. ( 30524332 )
2018
22
Acute anxiety disorder, major depressive disorder, bipolar disorder and schizophrenia are related to different patterns of nigrostriatal and mesolimbic dopamine dysfunction. ( 30269107 )
2018
23
Anxiety attacks with or without life-threatening situations, major depressive disorder, and suicide attempt: a nationwide community sample of Korean adults. ( 30273856 )
2018
24
The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. ( 30170282 )
2018
25
Risks of bipolar disorder, depressive disorder, and traumatic brain injury among siblings of patients with attention-deficit hyperactivity disorder. ( 30419534 )
2018
26
Problem behaviours and Major Depressive Disorder in adults with intellectual disability and autism. ( 30551323 )
2018
27
Maternal stress, prenatal medical illnesses and obstetric complications: Risk factors for schizophrenia spectrum disorder, bipolar disorder and major depressive disorder. ( 30458317 )
2018
28
Decreased Functional Connectivity in Insular Subregions in Depressive Episodes of Bipolar Disorder and Major Depressive Disorder. ( 30487732 )
2018
29
Altered resting-state cerebral blood flow and functional connectivity of striatum in bipolar disorder and major depressive disorder. ( 30500413 )
2018
30
Zinc and copper concentration do not differentiate bipolar disorder from major depressive disorder. ( 30218561 )
2018
31
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. ( 30287754 )
2018
32
Cluster analysis with MOODS-SR illustrates a potential bipolar disorder risk phenotype in young adults with remitted major depressive disorder. ( 30294823 )
2018
33
Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. ( 30320231 )
2018
34
Regional brain volume reductions in major depressive disorder and bipolar disorder: An analysis by voxel-based morphometry. ( 30328161 )
2018
35
A comparison of cognitive performance in bipolar disorder, major depressive disorder, unaffected first-degree relatives, and healthy controls. ( 30393945 )
2018
36
Abnormal intrinsic cerebro-cerebellar functional connectivity in un-medicated patients with bipolar disorder and major depressive disorder. ( 30206663 )
2018
37
Speed of antidepressant response to electroconvulsive therapy in bipolar disorder vs. major depressive disorder. ( 29803951 )
2018
38
Ruminative and dampening responses to positive affect in bipolar disorder and major depressive disorder. ( 30005179 )
2018
39
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. ( 29673146 )
2018
40
Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder. ( 29681025 )
2018
41
The circulating levels of CD4+ t helper cells are higher in bipolar disorder as compared to major depressive disorder. ( 29685287 )
2018
42
Local functional connectivity alterations in schizophrenia, bipolar disorder, and major depressive disorder. ( 29751242 )
2018
43
Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with major depressive disorder, bipolar disorder I, and major depressive with alcohol use disorders. ( 29454034 )
2018
44
13C-phenylalanine breath test and serum biopterin in schizophrenia, bipolar disorder and major depressive disorder. ( 29454221 )
2018
45
Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective. ( 29478517 )
2018
46
Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder: A systematic and critical review. ( 29331712 )
2018
47
Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. ( 29140583 )
2018
48
Comparing the screening property of the shortened versions of the Hypomania Checklist-32 (HCL-32): Cross-validation in Korean patients with bipolar disorder and major depressive disorder. ( 29149757 )
2018
49
Pattern recognition of magnetic resonance imaging-based gray matter volume measurements classifies bipolar disorder and major depressive disorder. ( 29156364 )
2018
50
Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. ( 30556736 )
2018

Variations for Mental Depression

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 CORT CRH HTR1A HTR2A HTR2C HTR7
2 12.34 COMT DCTN1 HTR1A POMC TPH2
4 11.91 BDNF GATA3 HTR1A HTR2A MAOA SLC6A4
5 11.78 GATA3 MAOA POMC
6
Show member pathways
11.73 HTR1A HTR2A HTR2C HTR7
7 11.58 FKBP5 GATA3 POMC
8 11.56 HTR1A HTR2A HTR2C HTR7 MAOA SLC6A4
9
Show member pathways
11.51 COMT SLC6A2 SLC6A4
10
Show member pathways
11.19 MAOA SLC6A2 SLC6A4 TPH2
11
Show member pathways
10.91 COMT MAOA SLC6A4
12 10.86 HTR2A HTR2C
13
Show member pathways
10.71 COMT MAOA
14 10.67 COMT MAOA
15 10.61 HTR1A HTR2A HTR2C HTR7 MAOA SLC6A4
16 10.28 CRH POMC

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.1 BDNF COMT HTR1A HTR2A HTR2C HTR7

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.81 COMT CRH OXT
2 circadian rhythm GO:0007623 9.8 HTR7 SLC6A4 TPH2
3 memory GO:0007613 9.73 BDNF HTR2A OXT SLC6A4
4 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.71 HTR1A HTR2A HTR7
5 behavioral fear response GO:0001662 9.7 DPP4 HTR1A HTR2C
6 response to estrogen GO:0043627 9.67 COMT CRH GATA3 TPH2
7 locomotory exploration behavior GO:0035641 9.63 CRH DPP4
8 neuron cellular homeostasis GO:0070050 9.63 DCTN1 SLC6A2
9 response to pain GO:0048265 9.63 COMT CRH SLC6A2
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.62 HTR1A HTR2A HTR2C HTR7
11 sleep GO:0030431 9.61 HTR2A OXT
12 catecholamine metabolic process GO:0006584 9.61 COMT MAOA
13 neurotransmitter catabolic process GO:0042135 9.6 COMT MAOA
14 monoamine transport GO:0015844 9.59 SLC6A2 SLC6A4
15 dopamine catabolic process GO:0042420 9.58 COMT MAOA
16 regulation of appetite GO:0032098 9.58 HTR2C POMC
17 vasoconstriction GO:0042310 9.58 HTR1A HTR7 SLC6A4
18 sperm ejaculation GO:0042713 9.57 OXT SLC6A4
19 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.56 HTR2A HTR2C
20 response to ether GO:0045472 9.55 CRH OXT
21 response to drug GO:0042493 9.5 COMT CRH GATA3 HTR2A HTR2C SLC6A2
22 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.49 HTR2A HTR2C
23 regulation of serotonin secretion GO:0014062 9.48 CRH HTR1A
24 behavior GO:0007610 9.43 HTR1A HTR2A HTR2C
25 serotonin receptor signaling pathway GO:0007210 9.33 HTR1A HTR2A HTR2C
26 chemical synaptic transmission GO:0007268 9.17 CORT CRH HTR1A HTR2A HTR2C HTR7
27 signal transduction GO:0007165 10.22 CRH GATA3 HTR1A HTR2A HTR2C HTR7
28 G protein-coupled receptor signaling pathway GO:0007186 10.11 CORT CRH HTR1A HTR2A HTR2C HTR7

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.62 CORT CRH OXT POMC
2 neuropeptide hormone activity GO:0005184 9.54 CORT CRH OXT
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR2A HTR2C HTR7
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A2 SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A2 SLC6A4
6 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
7 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR2A HTR2C HTR7
8 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR2C SLC6A4

Sources for Mental Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD